SCHEMBL5451399

SCHEMBL5451399

NC(=O)c1c(NC(=S)NC2CC2)sc2c1CCCC2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.64
ALDH1A1 P00352 11/20 0.63
MAPT P10636 7/20 0.63
HPGD P15428 5/20 0.63
KMT2A Q03164 4/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
RAB9A P51151 4/20 0.63
GAA P10253 3/20 0.63
MEN1 O00255 3/20 0.63
NPC1 O15118 3/20 0.63
LMNA P02545 3/20 0.63
CYP1A2 P05177 1/20 0.61
CYP2C19 P33261 1/20 0.61
MDM2 Q00987 1/20 0.61
KDM4E B2RXH2 2/20 0.60
TSHR P16473 3/20 0.58
HSD17B10 Q99714 2/20 0.58
MAPK10 P53779 1/20 0.58
ALOX15 P16050 1/20 0.57
ANO1 Q5XXA6 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5448254 0.83 CFTR (0.55) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL3922474 0.79 FLT3 (1.00) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL5455726 0.77 FLT3 (0.97) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL3128067 0.77 FLT3 (0.92) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL3914689 0.77 FLT3 (0.92) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL8288845 0.77 FLT3 (0.97) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL5448461 0.77 GAA (1.00) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL3914847 0.76 FLT3 (1.00) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL3126680 0.76 FLT3 (0.90) FLT3ALDH1A1MAPTHPGDKMT2A
SCHEMBL8288684 0.76 FLT3 (0.90) FLT3ALDH1A1MAPTHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885ALDH1A1 1153/4885MAPT 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.